Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
The Latest on: Colorectal cancers
via Google News
The Latest on: Colorectal cancers
- Celyad’s off-the-shelf CAR-T data in colorectal cancer early, but serious toxicities haven’t appearedon July 5, 2019 at 1:18 pm
Preliminary data from an early-stage clinical trial show that heavily pretreated metastatic colorectal cancer patients receiving an off-the-shelf CAR-T cell therapy with chemotherapy achieved ... […]
- Mayo Clinic Minute: Could a capsule detect colon polyps without a bowel prep?on July 5, 2019 at 9:32 am
Colon cancer screening guidelines state that people at average risk of colon cancer should get screened starting at age 50. Dr. Elizabeth Rajan says some people avoid screening because they dislike ... […]
- Researchers use AI to establish molecular tumor classification and prognosis in patients with colorectal canceron July 5, 2019 at 7:19 am
Treating physicians need information about the molecular subtype of the tumor if they are to provide targeted therapy for colorectal carcinoma. A research team from University Hospital Zurich and ... […]
- Microbial stages of colorectal canceron July 5, 2019 at 6:42 am
Colorectal cancers develop in a multistage process from polyploid adenomas to carcinomas and more advanced disease stages. Increasingly, some bacterial species in the gastrointestinal microbiota have ... […]
- 'Pick the Winner' Trial in Rectal Cancer: Chemoradiation Firston July 5, 2019 at 5:09 am
BARCELONA, Spain — Patients with locally advanced rectal cancer are more likely to achieve a pathologic complete response (pCR) if they are given chemoradiotherapy before chemotherapy as part of ... […]
- Metagenomics and transcriptomics data from human colorectal canceron July 5, 2019 at 2:15 am
Colorectal cancer is a heterogenous and mostly sporadic disease, the development of which is associated with microbial dysbiosis. Recent advances in subtype classification have successfully stratified ... […]
- RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal canceron July 5, 2019 at 1:26 am
Disabled tumor suppressor genes and hyperactive oncogenes greatly contribute to cell fates during cancer development because of their genetic alterations such as somatic mutations. However, little is ... […]
- Men who eat yogurt may have lower colon cancer riskon July 3, 2019 at 11:59 am
Men who eat at least two servings a week of yogurt may be lowering their risk for colorectal cancer, a recent study suggests. Researchers examined data on 32,606 male and 55,743 female health ... […]
- Role for Lateral Node Dissection in Low Rectal Canceron July 3, 2019 at 8:11 am
Use of lateral lymph node dissection -- a technique not commonly employed in the U.S. -- can be avoided in certain patients with low rectal cancer, but should be "seriously considered" for those with ... […]
- Colon and Rectal Cancer Drugs Market Impressively growing Opportunities and Global Business Forecast 2026on July 1, 2019 at 11:31 pm
Jul 02, 2019 (News AIM via COMTEX) -- Colon and rectal cancer are often grouped together, as they have many common features. Rate of colorectal cancer is increasing among the millennials in the U.S. ... […]
via Bing News